AstraZeneca receives EU approval for Tagrisso lung cancer treatment
23rd Dec 2024 10:13
(Alliance News) - AstraZeneca PLC on Monday said it has received approval in the European Union for Tagrisso, its non-small cell lung cancer treatment. Read More
(Alliance News) - AstraZeneca PLC on Monday said it has received approval in the European Union for Tagrisso, its non-small cell lung cancer treatment. Read More
(Alliance News) - Stocks in London were called to open down on Monday morning, as investors digest some unwelcome UK economic news at the start of a holiday-shortened week. Read More
(Alliance News) - Sales in China have suffered for AstraZeneca PLC after the arrest of its country president, the Financial Times reported on Wednesday, citing "two people familiar with the matter". Read More
(Alliance News) - Stock prices in London opened mostly lower on Monday, following another disappointing data release from China. Read More
Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pharmaceutical Co Ltd. Takeda receives a national reimbursement recommendation for the Fruzaqla cancer treatment in Spain this month. It is the first national reimbursement recommendation in Europe for the drug. "We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly," Hutchmed Chief Executive Officer Weiguo Su says. "It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer." Read More
Merck & Co Inc and AstraZeneca PLC - Rahway, New Jersey and Cambridge, England-based pharmaceutical firms - Report positive long-term results from phase three OlympiA trial on the use of Lynparza, generic name olaparib, to treat germline BRCA-mutated HER2-negative high-risk early breast cancer. Data showed clinically meaningful improvements in overall survival; invasive disease-free survival and distant disease-free survival, a decrease in the rate of cancer returning and spreading to other organs. After six years, OS rate was 87.5% compared to 83.2% in the placebo group, IDFS rate was 79.6% compared to 70.3% in placebo and DDFS was 83.5% compared to 75.7% in placebo. Lynparza is being jointly developed and commercialized by AstraZeneca and Merck and has been approved in the US, EU and Japan, among others. The EU indication also includes patients with locally advanced breast cancer. Read More
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday announced they have been granted a breakthrough therapy designation in the US to treat some sufferers of non-small cell lung cancer. Read More
(Alliance News) - London's FTSE 100 is called higher, while stocks in Hong Kong perked up amid after a slow start amid fresh hope for the Chinese economy. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Stock prices in London closed mixed on Thursday, ahead of key US data on Friday. Read More
(Alliance News) - AstraZeneca PLC on Thursday said the US Food & Drug Administration has approved its Imfinzi treatment for adults with limited-stage small cell lung cancer. Read More
(Alliance News) - AstraZeneca PLC on Wednesday appointed Iskra Reic as its new international executive vice president, replacing Leon Wang, who has been detained by Chinese authorities. Read More
(Alliance News) - Stocks in London ended mixed on Wednesday, with the FTSE 100 held back by falls in AstraZeneca plus uninspiring data, while mid-caps prospered amid rate cut hopes. Read More
(Alliance News) - London's FTSE 100 faltered, but European peers climbed and US stocks are called to open higher, with focus turning to US jobs data and the outcome of a key vote over in France. Read More
(Alliance News) - AstraZeneca PLC on Monday said its Truqap combination in a type of prostate cancer showed a statistically significant improvement in a form of progression-free survival. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - The FTSE 100 is called to open flat on Wednesday, after a hotter than expected UK inflation reading. Read More
(Alliance News) - Women with incurable breast cancer in England and Wales will not be offered a life-extending drug on the national health service after talks between the NHS spending watchdog and its manufacturer ended without an agreement on price for the third time. Read More
(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Friday last week and not separately reported by Alliance News: Read More
(Alliance News) - AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso as treatment for a form of lung cancer. Read More